Lexaria says US$7.9 million funding boost extends cash runway through 2027
LEXX•Management outlook
Management expects the added cash to fund operations through 2027; no additional equity or debt financings are planned in 2026.
Business development talks are expected to reduce Lexaria-funded R&D spending in 2027 by shifting costs to partners.
Funding boost extends runway
Lexaria Bioscience issued a response citing “aggressive” trading activity as the main driver of recent share-price pressure.
Net proceeds of USD 7.9 million from an Australian tax refund and warrant exercise lifted cash to about USD 4.60 per share. Financing was priced at USD 12.92 per share; shares outstanding total 2,100,000.
